Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Covington
Queensland Health
Colorcon
Merck
Mallinckrodt
Argus Health
Federal Trade Commission
Teva

Generated: November 17, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207795

« Back to Dashboard

NDA 207795 describes VYZULTA, which is a drug marketed by Bausch And Lomb and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the VYZULTA profile page.

The generic ingredient in VYZULTA is latanoprostene bunod. One supplier is listed for this compound. Additional details are available on the latanoprostene bunod profile page.
Summary for 207795
Tradename:VYZULTA
Applicant:Bausch And Lomb
Ingredient:latanoprostene bunod
Patents:5
Generic Entry Opportunity Date for 207795
Generic Entry Date for 207795*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION/DROPS;OPHTHALMIC

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 207795
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795 NDA Bausch & Lomb Incorporated 24208-504 24208-504-01 1 BOTTLE in 1 CARTON (24208-504-01) > 2.5 mL in 1 BOTTLE
VYZULTA latanoprostene bunod SOLUTION/DROPS;OPHTHALMIC 207795 NDA Bausch & Lomb Incorporated 24208-504 24208-504-02 1 BOTTLE in 1 CARTON (24208-504-02) > 2.5 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION/DROPS;OPHTHALMICStrength0.024%
Approval Date:Nov 2, 2017TE:RLD:Yes
Patent:➤ Try a Free TrialPatent Expiration:Jun 17, 2018Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Oct 3, 2025Product Flag?YSubstance Flag?YDelist Request?
Patented Use:REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION
Patent:➤ Try a Free TrialPatent Expiration:Jan 5, 2025Product Flag?YSubstance Flag?Delist Request?
Patented Use:REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Harvard Business School
Daiichi Sankyo
Fuji
Colorcon
Accenture
Covington
Baxter
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.